Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Expression of p63, bcl-2, bcl-6 and p16 in Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin

´ëÇѺ´¸®ÇÐȸÁö 2005³â 39±Ç 2È£ p.91 ~ 98
Zheng Zhen-Long, ±è¾Ö¸®, °è¿µÃ¶, ±èÀμ±, Zhang Xiang-Lan,
¼Ò¼Ó »ó¼¼Á¤º¸
 ( Zheng Zhen-Long ) 
°í·Á´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

±è¾Ö¸® ( Kim Ae-Ree ) 
°í·Á´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
°è¿µÃ¶ ( Kye Young-Chul ) 
°í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ÇǺΰúÇб³½Ç
±èÀμ± ( Kim In-Sun ) 
°í·Á´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
 ( Zhang Xiang-Lan ) 
°í·Á´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

Abstract


Background: Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the common malignant neoplasms of the skin. The p63 is a p53 homologue which is considered to be a reliable keratinocyte stem cell marker. Bcl-2 plays a key role in cell longevity by preventing apoptosis, whereas the bcl-6 gene functions as a transcriptional repressor. The p16-CDK4/6 complex arrests the cell cycle at G0/G1 phase. In the present study, the expression of p63, bcl-2, bcl-6, and p16 in BCC and SCC was evaluated.

Methods: Forty-seven BCCs and 43 SCCs were selected and microarrayed in paraffin blocks. Immunohistochemical analysis was performed with specific antibodies for bcl-2, bcl-6, p16 and p63.

Results: p63 was found to be expressed in all BCCs and SCCs. Bcl-2 was exclusively expressed in BCCs (100%), but there was negative expression in SCCs, whereas bcl-6 was positively expressed in 18.2% of SCCs, and was negative in BCCs. In SCCs, p16 was expressed at high frequency (47.7%) than in BCCs (14.9%). The expression of p16 was correlated with the histologic grades of SCCs.

Conclusion: The different patterns of bcl-2, bcl-6, p63 and p16 protein expression between BCCs and SCCs may represent the different histogenesis and morphologic features of two lesions.

Å°¿öµå

Carcinoma;Basal cell;Squamous cell;p63 protein;Proto-oncogene proteins bcl-2;Proto-oncogene protein bcl-6; Protein 16

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS